Minoryx Therapeutics
Minoryx Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for rare neurological and genetic metabolic disorders. The company advances CNS-penetrant small-molecule programs, with lead development candidates (for example, leriglitazone / MIN-102) designed to address neuroinflammation, mitochondrial dysfunction and disease progression in conditions such as X-linked adrenoleukodystrophy and Friedreich’s ataxia. Minoryx operates in drug discovery and clinical development, progressing candidates through regulatory and clinical pathways toward potential therapeutic use in orphan indications.
Leadership & Board
- Current Number of Employees
- 32
- Current LinkedIn Followers
- 9,489
Latest Estimated Valuation
- Estimated Valuation
- ―
- Total Amount Raised
- $31M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $31M
- Latest Funding Round
- Investment
- Post-Money Valuation
- ―
Employee Trend
Minoryx Therapeutics had 32 employees as of October 12, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Minoryx Therapeutics had 9,489 followers as of October 12, 2026. The number of followers increased by 42 (0.44%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Aug 10, 2025 | Investment | $31.40M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Centre for the Development of Industrial Technology | Investment |
Related News and Analysis
